Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P. Buikhuisen WA, et al. Lancet Oncol. 2013 May;14(6):543-51. doi: 10.1016/S1470-2045(13)70125-6. Epub 2013 Apr 12. Lancet Oncol. 2013. PMID: 23583604 Clinical Trial.
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P. Krug LM, et al. Among authors: buikhuisen wa. Lancet Oncol. 2015 Apr;16(4):447-56. doi: 10.1016/S1470-2045(15)70056-2. Epub 2015 Mar 20. Lancet Oncol. 2015. PMID: 25800891 Clinical Trial.
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar L, Disselhorst M, Klomp H, Hartemink K, Burgers S, Buikhuisen W, Baas P. Quispel-Janssen J, et al. J Thorac Oncol. 2018 Oct;13(10):1569-1576. doi: 10.1016/j.jtho.2018.05.038. Epub 2018 Jun 14. J Thorac Oncol. 2018. PMID: 29908324 Free article. Clinical Trial.
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
de Gooijer CJ, van der Noort V, Stigt JA, Baas P, Biesma B, Cornelissen R, van Walree N, van Heemst RC, Soud MY, Groen HJM, den Brekel AJS, Buikhuisen WA, Bootsma GP, Dammeijer F, van Tinteren H, Lalezari F, Aerts JG, Burgers JA; NVALT19 study group. de Gooijer CJ, et al. Among authors: buikhuisen wa. Lancet Respir Med. 2021 Jun;9(6):585-592. doi: 10.1016/S2213-2600(20)30362-3. Epub 2021 Jan 27. Lancet Respir Med. 2021. PMID: 33515500 Clinical Trial.
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
van der Wel JWT, Jebbink M, van den Broek D, Steinbusch LC, Theelen WSME, Ruiter G, Buikhuisen W, Burgers JA, Baas P, Vermeulen M, van der Noort V, Hashemi SMS, Bosch LJW, Monkhorst K, Smit EF, Boelens MC, de Langen AJ. van der Wel JWT, et al. Lung Cancer. 2024 Dec;198:107972. doi: 10.1016/j.lungcan.2024.107972. Epub 2024 Sep 28. Lung Cancer. 2024. PMID: 39556978
29 results